Elucidating the mechanism underlying incomplete immune recovery in people living with HIV through CD4⁺ and CD8⁺ T cell multi-omics
Marina Flores-Piñas(Institut de Recerca Biomèdica Catalunya Sud), Anna Rull(Instituto de Salud Carlos III), Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Marcos Elizalde-Horcada(Gobierno de Navarra), Beatriz Villar(Institut de Recerca Biomèdica Catalunya Sud), Josep Mallolas(Hospital Clínic de Barcelona), Sílvia Chafino(Instituto de Salud Carlos III), Alexy Inciarte(Universitat de Barcelona), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Joaquim Peraire(Instituto de Salud Carlos III), Eugènia Negredo(Instituto de Salud Carlos III), Julià Blanco(Instituto de Salud Carlos III), Pere Domingo(Hospital de Sant Pau), Yolanda M. Pacheco(Instituto de Biomedicina de Sevilla), Jordi Navarro(Vall d'Hebron Institut de Recerca), Verònica Alba, Paula Prieto(Hospital de Sant Pau), Anna Martí(Institut de Recerca Biomèdica Catalunya Sud)
Cited by 0
Related Papers
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013
|Journal of Infection|2016|89
Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection
|EBioMedicine|2019|81
Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection
|Journal of Virology|2017|78